Objective: Recent, large, randomized controlled trials (RCTs) showed no benefit of long-
acting injectable (LAI) antipsychotics over oral antipsychotics in preventing relapse in …

Background Evidence of comparative benefits of long-acting injectable antipsychotics (LAIs)
versus oral antipsychotics for schizophrenia has been inconsistent across study designs …

Background: While long-acting injectable antipsychotics (LAIs) are hoped to reduce high
relapse rates in schizophrenia, recent randomized controlled trials (RCTs) challenged the …

Compared with oral antipsychotics (OAPs), long-acting injectable antipsychotics (LAIs)
should improve medication adherence and reduce relapses in schizophrenia. However …

BackgroundAntipsychotic long-acting injections (LAIs) are often used in an attempt to
improve medication adherence in people with schizophrenia. AimsTo compare first …

Objective: Nonadherence is a major challenge in schizophrenia treatment. While long-acting
(depot) antipsychotic medications are often recommended to address adherence problems …

Importance of the field: Antipsychotic medications are the cornerstone of treatment in
schizophrenia, and a large body of data confirms the value of ongoing and continuous …

Despite their widespread use, long-acting injectable (LAI) antipsychotics (APs) are often
regarded with some negativity because of the assumption of punishment, control and …

The aim of the present article is to test at a meta-analytical level the efficacy and safety of
second-generation long-acting antipsychotic injections (SGLAI) in schizophrenia. Thirteen …

Background Long-acting injectable (LAI) antipsychotics, compared with oral antipsychotics
(OA), have been found to significantly improve patient outcomes, including reduced …